Skip to main content
Erschienen in: International Ophthalmology 6/2023

13.12.2022 | Original Paper

Albuminuria as a biomarker of severity in diabetic retinopathy and in the response to intravitreal treatment in diabetic macular edema

verfasst von: Ane Gibelalde, Asier Amenabar Alonso, Sergio Pinar-Sueiro, Ismene Bilbao-Garay, Leire Juaristi Eizmendi, Amaia Sampedro

Erschienen in: International Ophthalmology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Diabetic macular edema (DME) presents a suboptimal response to antiangiogenic treatment in approximately 30% of patients. We analyzed the relationship between renal function and response to antiangiogenic therapy in patients with DME.

Methods

A total of 367 patients were collected and distributed into three main groups: uncomplicated diabetic retinopathy (DR) group (n = 97), proliferative diabetic retinopathy (PDR) group (n = 94) and DME group (n = 175). Likewise, patients with DME were divided into two groups: responders to antiangiogenic drugs (n = 96) and non-responders to antiangiogenic drugs (n = 79). Age, type of diabetes, arterial hypertension (AHT), creatinine, HbA1c, albuminuria and glomerular filtration rate were analyzed. In the statistical analysis, chi-square test and t student were used to compare each group. The relationship between albuminuria and response to treatment in the DME group was studied with a binary logistic regression model, estimating odds ratio and their confidence intervals.

Results

There are differences between the three main groups in terms of the presence or not of albuminuria. The presence of albuminuria is greater in the group of patients with more severe DR (PDR and DME), compared to the uncomplicated DR group (p < 0.009). In the logistic regression analysis model, a positive relationship was found and the odds ratio for the albuminuria variable and is 2.78 (CI: 1.42–5.36).

Conclusions

The presence of albuminuria is associated with a higher degree of DR and worse response to antiangiogenic therapy in patients with DME in our series. Multidisciplinary teams would be necessary to reduce albuminuria and thus optimize the treatment of patients with DME.
Literatur
1.
Zurück zum Zitat Hou L, Shi Y, Wang S, Chen Q, Li Q, Zhao M et al (2020) Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. J Int Med Res 48(12):030006052096398CrossRef Hou L, Shi Y, Wang S, Chen Q, Li Q, Zhao M et al (2020) Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. J Int Med Res 48(12):030006052096398CrossRef
2.
3.
Zurück zum Zitat Gurung RL, FitzGerald LM, McComish BJ, Verma N, Burdon KP (2020) Identifying genetic risk factors for diabetic macular edema and the response to treatment. J Diab Res 2020:5016916. Gurung RL, FitzGerald LM, McComish BJ, Verma N, Burdon KP (2020) Identifying genetic risk factors for diabetic macular edema and the response to treatment. J Diab Res 2020:5016916.
4.
Zurück zum Zitat Usui-Ouchi A, Tamaki A, Sakanishi Y, Tamaki K, Mashimo K, Sakuma T et al (2021) Factors affecting a short-term response to Anti-VEGF therapy in diabetic macular edema. Life 11(2):83CrossRefPubMedPubMedCentral Usui-Ouchi A, Tamaki A, Sakanishi Y, Tamaki K, Mashimo K, Sakuma T et al (2021) Factors affecting a short-term response to Anti-VEGF therapy in diabetic macular edema. Life 11(2):83CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Zhuang X, Cao D, Yang D, Zeng Y, Yu H, Wang J et al (2019) Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study. BMJ Open 9(9):e031194CrossRefPubMedPubMedCentral Zhuang X, Cao D, Yang D, Zeng Y, Yu H, Wang J et al (2019) Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study. BMJ Open 9(9):e031194CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Liu ZY (2019) Association of urinary albumin excretion with central foveal thickness and intravitreal conbercept treatment frequency in patients with diabetic macular edema. Int J Ophthalmol 12(10):1598–1604CrossRefPubMedPubMedCentral Liu ZY (2019) Association of urinary albumin excretion with central foveal thickness and intravitreal conbercept treatment frequency in patients with diabetic macular edema. Int J Ophthalmol 12(10):1598–1604CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care 24(Suppl 1):S1–133. American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care 24(Suppl 1):S1–133.
8.
Zurück zum Zitat Romero-Aroca P, Baget-Bernaldiz M, Navarro-Gil R, Moreno-Ribas A, Valls-Mateu A, Sagarra-Alamo R et al (2018) Glomerular filtration rate and/or ratio of urine albumin to creatinine as markers for diabetic retinopathy: a ten-year follow-up study. J Diabetes Res 2018:1–9CrossRef Romero-Aroca P, Baget-Bernaldiz M, Navarro-Gil R, Moreno-Ribas A, Valls-Mateu A, Sagarra-Alamo R et al (2018) Glomerular filtration rate and/or ratio of urine albumin to creatinine as markers for diabetic retinopathy: a ten-year follow-up study. J Diabetes Res 2018:1–9CrossRef
9.
Zurück zum Zitat Morales-Buenrostro LE, Citlali Juárez-Combon S, Aldrete Velasco J, Rodríguez Alcocer AM (2017) Renal effects and nephroprotection induced by the SGLT2 inhibitor empagliflozin in patients with diabetes mellitus: A literature review. Revista de Nefrologia, Dialisis y Trasplante 37:48–61 Morales-Buenrostro LE, Citlali Juárez-Combon S, Aldrete Velasco J, Rodríguez Alcocer AM (2017) Renal effects and nephroprotection induced by the SGLT2 inhibitor empagliflozin in patients with diabetes mellitus: A literature review. Revista de Nefrologia, Dialisis y Trasplante 37:48–61
10.
Zurück zum Zitat Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, Vinik AI, Casellini CM (2017) Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab 102(12):4343–4410. Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, Vinik AI, Casellini CM (2017) Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab 102(12):4343–4410.
11.
Zurück zum Zitat Im JHB, Jin YP, Chow R, Yan P (2022) Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis. Surv Ophthalmol 67(4):1244–1251CrossRefPubMed Im JHB, Jin YP, Chow R, Yan P (2022) Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis. Surv Ophthalmol 67(4):1244–1251CrossRefPubMed
12.
Zurück zum Zitat Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136(3):257–269. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136(3):257–269.
13.
Zurück zum Zitat Furino C, Boscia F, Reibaldi M, Alessio G (2021) Intravitreal therapy for diabetic macular edema: an update. J Ophthalmol 2021:1–23. Furino C, Boscia F, Reibaldi M, Alessio G (2021) Intravitreal therapy for diabetic macular edema: an update. J Ophthalmol 2021:1–23.
14.
Zurück zum Zitat Park HC, Lee YK, Cho Aj, Han C hoon, Noh JW, Shin YJ, et al (2019) Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS ONE 14(7):e0220506. Park HC, Lee YK, Cho Aj, Han C hoon, Noh JW, Shin YJ, et al (2019) Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS ONE 14(7):e0220506.
15.
Zurück zum Zitat Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M (2008) Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4: Original article. Diabet Med 25(5):536–542CrossRefPubMed Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M (2008) Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4: Original article. Diabet Med 25(5):536–542CrossRefPubMed
16.
Zurück zum Zitat Keane WF, Eknoyan G (1999) Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33(5):1004–1010CrossRefPubMed Keane WF, Eknoyan G (1999) Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33(5):1004–1010CrossRefPubMed
17.
Zurück zum Zitat Cignarelli M, Lamacchia O, Gesualdo L, Pilotti A, Pacilli A, Santini SA, De Cosmo S (2011) Increased cardiovascular risk among type 2 diabetic patients with high-normal albuminuria and no evidence of kidney impairment. Nutr Metab Cardiovasc Dis 21(2):e5-6CrossRefPubMed Cignarelli M, Lamacchia O, Gesualdo L, Pilotti A, Pacilli A, Santini SA, De Cosmo S (2011) Increased cardiovascular risk among type 2 diabetic patients with high-normal albuminuria and no evidence of kidney impairment. Nutr Metab Cardiovasc Dis 21(2):e5-6CrossRefPubMed
18.
Zurück zum Zitat Lee MK, Han KD, Lee JH, Sohn SY, Hong OK, Jeong JS et al (2017) Normal-to-mildly increased albuminuria predicts the risk for diabetic retinopathy in patients with type 2 diabetes. Sci Rep 7(1):11757CrossRefPubMedPubMedCentral Lee MK, Han KD, Lee JH, Sohn SY, Hong OK, Jeong JS et al (2017) Normal-to-mildly increased albuminuria predicts the risk for diabetic retinopathy in patients with type 2 diabetes. Sci Rep 7(1):11757CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kar D, Gillies C, Nath M, Khunti K, Davies MJ, Seidu S (2019) Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 56(8):839–850CrossRefPubMedPubMedCentral Kar D, Gillies C, Nath M, Khunti K, Davies MJ, Seidu S (2019) Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 56(8):839–850CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Zhang W, Liu C, Ji L, Wang J (2020) For the ATTEND investigators. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. J Clin Hypertens 22(2):212–20. Zhang W, Liu C, Ji L, Wang J (2020) For the ATTEND investigators. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. J Clin Hypertens 22(2):212–20.
21.
Zurück zum Zitat Skyler JS (1996) Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am 25(2):243–54. Skyler JS (1996) Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am 25(2):243–54.
22.
Zurück zum Zitat Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I (2016) The impact of systemic factors on clinical response to Ranibizumab for diabetic macular edema. Ophthalmology 123(7):1581–1587CrossRefPubMed Singh RP, Habbu K, Ehlers JP, Lansang MC, Hill L, Stoilov I (2016) The impact of systemic factors on clinical response to Ranibizumab for diabetic macular edema. Ophthalmology 123(7):1581–1587CrossRefPubMed
23.
Zurück zum Zitat Ohigashi M, Osugi K, Kusunoki Y, Washio K, Matsutani S, Tsunoda T et al (2021) Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro- d -glucitol. J Diabetes Investig 12(6):940–949CrossRefPubMed Ohigashi M, Osugi K, Kusunoki Y, Washio K, Matsutani S, Tsunoda T et al (2021) Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro- d -glucitol. J Diabetes Investig 12(6):940–949CrossRefPubMed
24.
Zurück zum Zitat Eldor R, Roitman E, Merzon E, Toledano Y, Alves C, Tsur A (2022) Flash glucose monitoring in Israel: understanding real-world associations between self-monitoring frequency and metrics of glycemic control. Endocr Pract 28(5):472–478CrossRefPubMed Eldor R, Roitman E, Merzon E, Toledano Y, Alves C, Tsur A (2022) Flash glucose monitoring in Israel: understanding real-world associations between self-monitoring frequency and metrics of glycemic control. Endocr Pract 28(5):472–478CrossRefPubMed
25.
Zurück zum Zitat Chaturvedi N, Stevens L, Fuller JH (1997) Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes Care 20(8):1266–1272CrossRefPubMed Chaturvedi N, Stevens L, Fuller JH (1997) Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes Care 20(8):1266–1272CrossRefPubMed
26.
Zurück zum Zitat Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63(1):225–32. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63(1):225–32.
27.
Zurück zum Zitat Butler AE, English E, Kilpatrick ES, Östlundh L, Chemaitelly HS, Abu-Raddad LJ et al (2021) Diagnosing type 2 diabetes using Hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. Acta Diabetol 58(3):279–300CrossRefPubMed Butler AE, English E, Kilpatrick ES, Östlundh L, Chemaitelly HS, Abu-Raddad LJ et al (2021) Diagnosing type 2 diabetes using Hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. Acta Diabetol 58(3):279–300CrossRefPubMed
28.
Zurück zum Zitat Hwang H, Lee H, Kim JY, Lee S, Seo EJ, Chae JB, Kim DY (2021) Systemic factors and early treatment response to intravitreal injection for diabetic macular edema: the role of renal function. Retina 41(6):1275–1282PubMed Hwang H, Lee H, Kim JY, Lee S, Seo EJ, Chae JB, Kim DY (2021) Systemic factors and early treatment response to intravitreal injection for diabetic macular edema: the role of renal function. Retina 41(6):1275–1282PubMed
Metadaten
Titel
Albuminuria as a biomarker of severity in diabetic retinopathy and in the response to intravitreal treatment in diabetic macular edema
verfasst von
Ane Gibelalde
Asier Amenabar Alonso
Sergio Pinar-Sueiro
Ismene Bilbao-Garay
Leire Juaristi Eizmendi
Amaia Sampedro
Publikationsdatum
13.12.2022
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 6/2023
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-022-02604-y

Weitere Artikel der Ausgabe 6/2023

International Ophthalmology 6/2023 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.